|

SHR-1701 Clinical Trials

3 actively recruiting trials

▲ +1 trial since July 2026

Pipeline

Phase 2: 2

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University1
  • Nanjing Tianyinshan Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer3
  • Liver Disease1
  • Gastroesophageal Junction Adenocarcinoma1
  • Gastric Adenocarcinoma1
  • Hepatocellular Carcinoma (HCC)1

Other3 trials

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Phase 2
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.